摘要 |
This invention provides compounds of Formula (I) having the structure wherein A is (a) or (b), Q is (c) or (d); B is carbon or nitrogen; D is oxygen, sulfur, or nitrogen; E is carbon or nitrogen; X is carbon, nitrogen, oxygen, or sulfur; Y is a bond, methylene, C(O), or CH(OH); Z is CH=CH, nitrogen, oxygen, or sulfur; the dashed line of Q represents an optional double bond; R<1> is alkyl of 1 to 12 carbons, aryl of 6-10 carbon atoms, aralkyl of 7-15 carbon atoms, halogen, trifluoromethyl, alkoxy of 1-6 carbon atoms, Het-alkyl wherein the alkyl moiety contains 1-6 carbon atoms, or aryl of 6-10 carbon atoms mono-, di-, or tri-substituted with trifluoromethyl, alkyl of 1-6 carbon atoms or, alkoxy of 1-6 carbon atoms; Het is (e) or (f); R<7> is alkylene of 1 to 3 carbon atoms, G is oxygen, sulfur or nitrogen; R<2> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, or trifluoromethyl; R<3> and R<4> are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, halogen, trifluoromethyl, alkoxy of 1-6 carbon atoms, aryl of 6-10 carbon atoms mono-, di-, or tri-substituted with trifluoromethyl, alkyl of 1-6 carbon atoms or, alkoxy of 1-6 carbon atoms, nitro, alkylsulfamide; arylsulfamide, cycloakyl of 3-8 carbon atoms or a heterocyclic ring containing 5 to ring 7 atom rings having 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur; R<5> is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, or aralkyl of 7-15 carbon atoms; R<6> is hydrogen, -OR<5>, or -OCOR<5>; with the proviso that when R<1> is halogen, Y is a bond, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. |